The impact of hypoglycaemia on quality of life among adults with type 1 diabetes: Results from “YourSAY: Hypoglycaemia”

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 721 KB, PDF-dokument

  • Hannah Chatwin
  • Melanie Broadley
  • Christel Hendrieckx
  • Jill Carlton
  • Simon Heller
  • Stephanie A. Amiel
  • Bastiaan de Galan
  • Rory J. McCrimmon
  • Pedersen-Bjergaard, Ulrik
  • Frans Pouwer
  • Jane Speight
  • on behalf of the Hypo-RESOLVE consortium

Aims: Research on hypoglycaemia and quality of life (QoL) has focused mostly on severe hypoglycaemia and psychological outcomes, with less known about other aspects of hypoglycaemia (e.g., self-treated episodes) and impacts on other QoL domains (e.g., relationships). Therefore, we examined the impact of all aspects of hypoglycaemia on QoL in adults with type 1 diabetes (T1DM). Methods: Participants completed an online survey, including assessment of hypoglycaemia-specific QoL (using the 12-item Hypoglycaemia Impact Profile). Mann-Whitney U tests examined differences in hypoglycaemia-specific QoL by hypoglycaemia frequency, severity, and awareness. Hierarchical linear regression examined associations with QoL. Results: Participants were 1028 adults with T1DM (M ± SD age: 47 ± 15 years; diabetes duration: 27 ± 16 years). Severe and self-treated hypoglycaemia and impaired awareness negatively impacted on overall QoL and several QoL domains, including leisure activities, physical health, ability to keep fit/be active, sleep, emotional well-being, spontaneity, independence, work/studies, and dietary freedom. Diabetes distress was most strongly associated with hypoglycaemia-specific QoL, followed by generic emotional well-being, fear of hypoglycaemia, and confidence in managing hypoglycaemia. Hypoglycaemia frequency and awareness were no longer significantly associated with QoL once psychological factors were considered. Conclusions: Hypoglycaemia negatively impacts on several QoL domains. Psychological factors supersede the effect of hypoglycaemia frequency and awareness in accounting for this negative impact.

OriginalsprogEngelsk
Artikelnummer108232
TidsskriftJournal of Diabetes and its Complications
Vol/bind37
Antal sider9
ISSN1056-8727
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 777460. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and T1D Exchange, JDRF, International Diabetes Federation (IDF), The Leona M. and Harry B. Helmsley Charitable Trust. JS and CH are supported by core funding to the Australian Centre for Behavioural Research in Diabetes provided by the collaboration between Diabetes Victoria and Deakin University. SAA has served on advisory boards for Medtronic and Novo Nordisk and lectured at educational events sponsored by Novo Nordisk and Sanofi. SH has served on advisory boards and undertaken consultancy for Eli Lilly, Novo Nordisk, Zealand Pharma, Zucara Pharmaceuticals, and Vertex, for which the University of Sheffield has received remuneration. SH has lectured at educational events sponsored by Novo Nordisk, chairs the International Hypoglycaemia Study Group. UPB has served on advisory boards and received lecture fees from Novo Nordisk and Sanofi. JS has served on advisory boards and undertaken speaking engagements for AstraZeneca, Insulet, Novo Nordisk, Roche Diabetes Care, and Sanofi, and has received in-kind support and/or grant funding from Abbott Diabetes Care, AstraZeneca, Medtronic, and Sanofi.

Funding Information:
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking ( JU ) under grant agreement No 777460 . The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and T1D Exchange, JDRF , International Diabetes Federation ( IDF ), The Leona M. and Harry B. Helmsley Charitable Trust . JS and CH are supported by core funding to the Australian Centre for Behavioural Research in Diabetes provided by the collaboration between Diabetes Victoria and Deakin University . SAA has served on advisory boards for Medtronic and Novo Nordisk and lectured at educational events sponsored by Novo Nordisk and Sanofi. SH has served on advisory boards and undertaken consultancy for Eli Lilly, Novo Nordisk, Zealand Pharma, Zucara Pharmaceuticals, and Vertex, for which the University of Sheffield has received remuneration. SH has lectured at educational events sponsored by Novo Nordisk , chairs the International Hypoglycaemia Study Group. UPB has served on advisory boards and received lecture fees from Novo Nordisk and Sanofi. JS has served on advisory boards and undertaken speaking engagements for AstraZeneca, Insulet, Novo Nordisk, Roche Diabetes Care, and Sanofi, and has received in-kind support and/or grant funding from Abbott Diabetes Care, AstraZeneca, Medtronic, and Sanofi.

Publisher Copyright:
© 2022 The Authors

ID: 321874827